Tirzepatide
FDA-approved
Brand names: Zepbound, Mounjaro
Tirzepatide is a dual GLP-1/GIP agonist — the second receptor target beyond GLP-1-only drugs — approved for diabetes (Mounjaro) and chronic weight management (Zepbound), with the largest approved-drug weight-loss numbers to date.
Label reference — not medical advice
Static FDA prescribing-information dosing schedule, shown for reference only. This is not personalized to you and is not a recommendation — always follow what your prescriber directed.
| Phase | Dose | Frequency |
|---|---|---|
| Starting dose | 2.5 mg | once weekly |
| Titration step 2 | 5 mg | once weekly |
| Titration step 3 | 7.5 mg | once weekly |
| Titration step 4 | 10 mg | once weekly |
| Titration step 5 | 12.5 mg | once weekly |
| Maintenance | 15 mg | once weekly |
Side effects
Common
Nausea, Diarrhea, Decreased appetite, Vomiting, Constipation, Injection site reactions
Serious (less common)
Pancreatitis, Gallbladder disease, Acute kidney injury, Severe gastrointestinal disease
When to contact a clinician
- Severe, persistent abdominal pain (possible pancreatitis) — seek care immediately
- Signs of severe allergic reaction (swelling, trouble breathing)
- Persistent vomiting or diarrhea leading to dehydration
- Decreased urination (possible kidney injury)
News & trials
Live news feed coming soon. In the meantime, see the Learn hub for the latest cited articles.